TRX Stock Overview
A medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Tissue Regenix Group plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.62 |
52 Week High | UK£0.73 |
52 Week Low | UK£0.48 |
Beta | 1.46 |
1 Month Change | 0.81% |
3 Month Change | -10.79% |
1 Year Change | 21.57% |
3 Year Change | -3.13% |
5 Year Change | -89.31% |
Change since IPO | -92.91% |
Recent News & Updates
Recent updates
Shareholder Returns
TRX | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | -0.1% | -0.6% |
1Y | 21.6% | -21.0% | 7.7% |
Return vs Industry: TRX exceeded the UK Biotechs industry which returned -20.7% over the past year.
Return vs Market: TRX exceeded the UK Market which returned 6.5% over the past year.
Price Volatility
TRX volatility | |
---|---|
TRX Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TRX has not had significant price volatility in the past 3 months.
Volatility Over Time: TRX's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 82 | Danny Lee | www.tissueregenix.com |
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.
Tissue Regenix Group plc Fundamentals Summary
TRX fundamental statistics | |
---|---|
Market cap | UK£43.66m |
Earnings (TTM) | -UK£1.35m |
Revenue (TTM) | UK£23.19m |
1.9x
P/S Ratio-32.4x
P/E RatioIs TRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRX income statement (TTM) | |
---|---|
Revenue | US$29.49m |
Cost of Revenue | US$15.45m |
Gross Profit | US$14.04m |
Other Expenses | US$15.75m |
Earnings | -US$1.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.024 |
Gross Margin | 47.60% |
Net Profit Margin | -5.81% |
Debt/Equity Ratio | 20.4% |
How did TRX perform over the long term?
See historical performance and comparison